Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, Lintermans B, Goossens S, Lammens T, Van Roy N, Touzart A, Jenni S, Tsai YC, Lovisa F, Mussolin L, Serafin V, Van Nieuwerburgh F, Deforce D, Uyttebroeck A, Tousseyn T, Burkhardt B, Klapper W, De Moerloose B, Benoit Y, Macintyre E, Bourquin JP, Basso G, Accordi B, Bornhauser B, Meijerink J, Vandenberghe P, Van Vlierberghe P.

Haematologica. 2019 Jan;104(1):e17-e20. doi: 10.3324/haematol.2018.199257. Epub 2018 Aug 3. No abstract available.

2.

Small RNAs in Circulating Exosomes of Cancer Patients: A Minireview.

Bortoluzzi S, Lovisa F, Gaffo E, Mussolin L.

High Throughput. 2017 Oct 6;6(4). pii: E13. doi: 10.3390/ht6040013. Review.

3.

Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.

Lovisa F, Zecca M, Rossi B, Campeggio M, Magrin E, Giarin E, Buldini B, Songia S, Cazzaniga G, Mina T, Acquafredda G, Quarello P, Locatelli F, Fagioli F, Basso G.

Br J Haematol. 2018 Mar;180(5):680-693. doi: 10.1111/bjh.15086. Epub 2018 Jan 23.

PMID:
29359790
4.

Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma.

Pomari E, Lovisa F, Carraro E, Primerano S, D'Amore ESG, Bonvini P, Nigro LL, Vito R, Vinti L, Farruggia P, Pillon M, Basso G, Basso K, Mussolin L.

Oncotarget. 2017 Nov 11;8(64):107886-107898. doi: 10.18632/oncotarget.22386. eCollection 2017 Dec 8.

5.

Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors.

Peron M, Lovisa F, Poli E, Basso G, Bonvini P.

PLoS One. 2015 Jul 6;10(7):e0132330. doi: 10.1371/journal.pone.0132330. eCollection 2015.

6.

Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience.

Mussolin L, Buldini B, Lovisa F, Carraro E, DisarĂ² S, Lo Nigro L, d'Amore ES, Pillon M, Basso G.

Pediatr Blood Cancer. 2015 Nov;62(11):1906-13. doi: 10.1002/pbc.25607. Epub 2015 Jun 24.

PMID:
26109265
7.

ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.

Lovisa F, Cozza G, Cristiani A, Cuzzolin A, Albiero A, Mussolin L, Pillon M, Moro S, Basso G, Rosolen A, Bonvini P.

PLoS One. 2015 Apr 13;10(4):e0121378. doi: 10.1371/journal.pone.0121378. eCollection 2015.

8.

IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis.

Lovisa F, Mussolin L, Corral L, Pillon M, Cazzaniga G, Biondi A, Rosolen A.

Lab Invest. 2009 Oct;89(10):1182-6. doi: 10.1038/labinvest.2009.81. Epub 2009 Aug 10.

Supplemental Content

Loading ...
Support Center